tetano
Editor, Senior Moderator
IDCases
. 2020 May 22;21:e00837.
doi: 10.1016/j.idcr.2020.e00837. eCollection 2020.
Treatment of Severe Pneumonia Due to COVID-19 With Peginterferon Alfa 2a
Rania M El-Lababidi[SUP] 1 [/SUP], Mohamad Mooty[SUP] 2 [/SUP], Maria-Fernanda Bonilla[SUP] 3 [/SUP], Nouran M Salem[SUP] 4 [/SUP]
Affiliations
Abstract
The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
Keywords: Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.
. 2020 May 22;21:e00837.
doi: 10.1016/j.idcr.2020.e00837. eCollection 2020.
Treatment of Severe Pneumonia Due to COVID-19 With Peginterferon Alfa 2a
Rania M El-Lababidi[SUP] 1 [/SUP], Mohamad Mooty[SUP] 2 [/SUP], Maria-Fernanda Bonilla[SUP] 3 [/SUP], Nouran M Salem[SUP] 4 [/SUP]
Affiliations
- PMID: 32483527
- PMCID: PMC7242210
- DOI: 10.1016/j.idcr.2020.e00837
Abstract
The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
Keywords: Coronavirus disease 2019; Interferons; Pegylated interferon alfa 2a; SARS-CoV-2.